Key Highlights:
- Lupin has launched Formoflo-G MDI in India following DCGI approval, described as the world’s first fixed-dose triple-combination metered-dose inhaler combining glycopyrronium bromide, formoterol fumarate and fluticasone propionate.
- The twice-daily inhaler is indicated for long-term management of moderate to severe COPD and combines three established therapies into a single fixed-strength formulation, targeting a disease affecting more than 55 million people in India.
- The launch strengthens Lupin’s respiratory portfolio and follows its #2 ranking in India’s respiratory therapy segment, according to IQVIA MAT March 2026, as the company focuses on differentiated therapies for unmet patient needs.
Implications:
Lupin’s launch of Formoflo-G strengthens its respiratory leadership by offering a differentiated triple-combination MDI for COPD. The single-inhaler approach could improve treatment convenience and adherence, helping Lupin capture share in India’s large COPD market while intensifying competition in triple inhaled therapies.
Source: Express Pharma
